Fagan SC - Search Results

1

Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.

Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, Ergul A, Hess DC. Fagan SC, et al. J Hypertens. 2006 Mar;24(3):535-9. doi: 10.1097/01.hjh.0000209990.41304.43. J Hypertens. 2006. PMID: 16467657

2

Pharmacology and clinical experience with simvastatin.

Hess DC, Fagan SC. Hess DC, et al. Among authors: fagan sc. Expert Opin Pharmacother. 2001 Jan;2(1):153-63. doi: 10.1517/14656566.2.1.153. Expert Opin Pharmacother. 2001. PMID: 11336576 Review.

3

Role of angiotensin-converting-enzyme inhibitors in stroke prevention.

Fagan SC, Lee LA, Hess DC. Fagan SC, et al. Am J Health Syst Pharm. 2003 Apr 15;60(8):788-93. doi: 10.1093/ajhp/60.8.788. Am J Health Syst Pharm. 2003. PMID: 12749165 No abstract available.

4

Hemorrhagic transformation is related to the duration of occlusion and treatment with tissue plasminogen activator in a nonembolic stroke model.

Fagan SC, Nagaraja TN, Fenstermacher JD, Zheng J, Johnson M, Knight RA. Fagan SC, et al. Neurol Res. 2003 Jun;25(4):377-82. doi: 10.1179/016164103101201526. Neurol Res. 2003. PMID: 12870264

5

Tracking trends in secondary stroke prevention strategies.

Carswell JL, Beard KA, Chevrette MM, Pardue CN, Hess DC, Fagan SC. Carswell JL, et al. Among authors: fagan sc. Ann Pharmacother. 2004 Feb;38(2):215-9. doi: 10.1345/aph.1D190. Epub 2003 Dec 23. Ann Pharmacother. 2004. PMID: 14742753

6

SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury.

Hill WD, Hess DC, Martin-Studdard A, Carothers JJ, Zheng J, Hale D, Maeda M, Fagan SC, Carroll JE, Conway SJ. Hill WD, et al. Among authors: fagan sc. J Neuropathol Exp Neurol. 2004 Jan;63(1):84-96. doi: 10.1093/jnen/63.1.84. J Neuropathol Exp Neurol. 2004. PMID: 14748564

7

Single slice method for quantification of hemorrhagic transformation using direct ELISA.

Hilali HM, Simpkins AN, Hill WD, Waller JL, Knight RA, Fagan SC. Hilali HM, et al. Among authors: fagan sc. Neurol Res. 2004 Jan;26(1):93-8. doi: 10.1179/016164104773026606. Neurol Res. 2004. PMID: 14977065

8

Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection.

Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A, Feuerstein G, Hess DC. Fagan SC, et al. Exp Neurol. 2004 Apr;186(2):248-51. doi: 10.1016/j.expneurol.2003.12.006. Exp Neurol. 2004. PMID: 15026261

9

Low dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats.

Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, Hill WD, Feuerstein G, Hess DC. Xu L, et al. Among authors: fagan sc. BMC Neurol. 2004 Apr 26;4:7. doi: 10.1186/1471-2377-4-7. BMC Neurol. 2004. PMID: 15109399 Free PMC article.

10

Targets for vascular protection after acute ischemic stroke.

Fagan SC, Hess DC, Hohnadel EJ, Pollock DM, Ergul A. Fagan SC, et al. Stroke. 2004 Sep;35(9):2220-5. doi: 10.1161/01.STR.0000138023.60272.9e. Epub 2004 Jul 29. Stroke. 2004. PMID: 15284446 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters